

GROWTH HORMONE

Sermorelin

GRF 1–29

First 29 residues of native human GHRH. Stimulates physiological pulsatile GH release.

MECHANISM GHRH receptor agonist (endogenous sequence GRF 1–29)	DOSAGE 200–500 mcg nightly SC	HALF-LIFE 10–20 minutes (pituitary effect persists)	FORMAT Lyophilised powder
--	---	---	-------------------------------------

BATCH NU-SER-4564	LOT 445564	CAS 86168-78-7	FORMULA C149H246N44O...	ISSUED 2025-10-23	RETEST 2026-10-23
-----------------------------	----------------------	--------------------------	-----------------------------------	-----------------------------	-----------------------------

OVERVIEW

Sermorelin is the first 29 amino acids of endogenous human GHRH (the active receptor-binding domain). It stimulates pituitary GH release via the GHRH receptor while preserving the hypothalamic–pituitary feedback axis. Because sermorelin works within the natural regulatory system rather than bypassing it, GH levels cannot exceed physiological peaks.

MECHANISM OF ACTION

GHRH receptor agonist (endogenous sequence GRF 1–29)

KEY RESEARCH BENEFITS

- Preserves hypothalamic–pituitary feedback — cannot overshoot
- Nightly administration aligns with natural GH pulse
- Lean-mass preservation in sarcopenia research
- Improved slow-wave sleep depth
- Fat loss via sustained IGF-1 elevation

RESEARCH NOTES

FDA-approved (as Geref) for paediatric GH deficiency. Adult anti-ageing and body-composition studies show IGF-1 normalisation and improved sleep architecture.

STORAGE & STABILITY

Lyophilised: -20 °C, stable >=24 months. Reconstituted: 2–8 °C, use within 14 days.